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TheglycoproteinHA(haemagglutinin)onthesurfaceofinﬂuenza
A virus plays a central role in recognition and binding to speciﬁc
hostcell-surfaceglycanreceptorsandinfusionofviralmembrane
to the host nuclear membrane during viral replication. Given the
abundance of HA on the viral surface, this protein is also the
primary target for host innate and adaptive immune responses.
Although addition of glycosylation sites on HA are a part of viral
evolution to evade the host immune responses, there are speciﬁc
glycosylationsitesthatareconservedduringmostoftheevolution
of the virus. In the present study, it was demonstrated that one
such conserved glycosylation site at Asn
91 in H1N1 HA critically
governs the glycan receptor-binding speciﬁcity and hence would
potentially impinge on the host adaptation of the virus.
Key words: glycan receptor, glycosylation, haemagglutinin,
H1N1, inﬂuenza virus.
INTRODUCTION
The speciﬁc binding of HA (haemagglutinin), a glycoprotein
on the surface of inﬂuenza A virus, to glycan receptors on the
host cell surface is one of the critical factors that govern host
infection and adaptation of the virus [1–3]. HA is a homotrimeric
transmembrane protein where each monomer has an ectodomain
consisting of a globular head, which harbours the glycan
RBS (receptor-binding site), and a stem region [4]. The host
glycan receptors for HA are sialylated glycans [complex glycans
terminated by sialic acid such as Neu5Ac (N-acetylneuraminic
acid)].GlycansterminatedbyNeu5Acthatisα2→6-linkedtothe
penultimate sugar are predominantly expressed in human upper
respiratory epithelia (henceforth referred to as human receptors)
and serve as receptors for human-adapted inﬂuenza A viruses
[5,6]. On the other hand, glycans terminating in Neu5Ac that is
α2→3-linked to the penultimate sugar residue serve as receptors
for the avian-adapted inﬂuenza viruses (henceforth referred to
as avian receptors) [7]. Given the location of HA on the viral
surface, this protein is also the primary antigen for the host
immune response. Selection pressure from innate and adaptive
host immunity drives HA to acquire mutations in order for the
virus to escape host defences. These mutations are predominantly
in the antigenic sites on HA that are proximal to the RBS
(since interfering with receptor binding is the primary target for
neutralizing antibodies). Therefore the mutations also impinge on
the glycan receptor-binding properties of HA [8].
In addition to acquiring mutations that change antigenic sites
on HA, inﬂuenza viruses acquire mutations that add or remove
glycosylation sites on HA. Amino acid substitutions that lead to
the sequence motifs (or sequons) required for glycosylation in the
globular head domain of HA are believed to efﬁciently generate
antigenic variants [9]. The complex glycans that are linked to the
glycosylation sites are involved in masking the antigenic epitopes
and have also been shown to play critical roles in maintaining
the structural stability and modulating function of HA [10–12].
The glycans near the cleavage site and in the stem region of HA
modulateproteolyticactivationandmaintainHAinthemetastable
form required for fusion activity [10].
Understanding the role of glycosylation on HA on its
glycan receptor-binding properties has been an active area of
research. Among the different types of glycosylation, N-linked
glycosylation involving attachment of complex glycans to an
asparagine residue in a consensus sequon (Asn-Xaa-Ser/Thr,
where Xaa is any amino acid except proline) has been the focus
of many studies.
Molecular dynamics simulation studies predicted that HA
glycansmayforminteractionsnearthebindingpockettoinﬂuence
receptor binding [11]. Site-directed mutagenesis to knock out
glycosylation sites on HA [10] or modifying structure of N-
linked glycans on the virus by enzymatic treatment or transgenic
cell lines [12] have shown distinct changes in glycan receptor-
binding speciﬁcity. Site-speciﬁc loss-of-glycosylation mutations
have also been shown to correlate with sensitivity to the innate
immune response in mice [13].
A systematic sequence analysis of H1N1 HAs from 1918
pandemic to the 2009 pandemic strains (Supplementary Table
S1 at http://www.BiochemJ.org/bj/444/bj4440429add.htm) has
revealed that, although there are differences in the number and
location of N-linked glycosylation sites in these HAs, there are
speciﬁc conserved glycosylation sites [14]. In the present study,
these conserved glycosylation sites were mapped on to the crystal
structure of H1N1 HA (PDB code 1RUZ). Through structural
analysis of the molecular contacts between glycosylation sites
and the RBS, it was shown that glycosylation at the Asn
91
(numbering based on PDB code 1RUZ) sequon (conserved in
most H1N1 HAs) was positioned to interact with the RBS of
HA. On the basis of this analysis, it was hypothesized that loss
of glycosylation at this sequon would affect receptor-binding
properties of H1 HA. To test this hypothesis, three HAs derived
fromthe1918pandemicH1N1viruswithdistinctglycanreceptor
speciﬁcities were deglycosylated at Asn
91 through site-directed
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mutagenesis. The binding properties of the mutant HAs were
quantitativelycharacterizedusingadose-dependentdirectglycan-
binding analysis using a glycan array platform. Through these
analyses, it was demonstrated that loss of glycosylation affected
human receptor binding of human HA, but not avian receptor
binding of avian HA. Furthermore, using MALDI (matrix-
assisted laser-desorption ionization)-MS and MS/MS (tandem
MS) analyses, it was shown that this sequon predominantly
comprises high-mannose-type glycans in the wild-type H1N1
HAs.
MATERIALS AND METHODS
HAs used in the present study
TheHAfromtheprototypic1918H1N1pandemicstrain(A/South
Carolina/1/18 or SC18), a single amino acid D225G mutant
of SC18 HA (referred to as NY18) and a two amino acid
D190E/D225G mutant of SC18 HA (referred to as AV18) were
used.
Site-directed mutagenesis of HA
Site-directed mutagenesis was carried out with the QuikChange®
multi site-directed mutagenesis kit (Stratagene). The primer
used for mutagenesis was designed by using the Internet-
based program Primer3 (http://frodo.wi.mit.edu/primer3/) and
synthesized by IDT (Integrated DNA Technologies). The primer





by DNA sequencing at Genewhiz (Cambridge, MA, U.S.A.).
Cloning, baculovirus synthesis, expression and puriﬁcation of HA
Brieﬂy, recombinant baculoviruses with the wild-type or mutant
HA gene respectively were used to infect [MOI (multiplicity of
infection)of1]suspensionculturesofSf9insectcells(Invitrogen)
cultured in BD Baculogold Max-XP SFM (BD Biosciences).
The infection was monitored and the conditioned medium was
harvested 3–4 days after infection. The soluble HA from the
harvested conditioned medium was puriﬁed using nickel-afﬁnity
chromatography (HisTrap HP columns; GE Healthcare). Eluting
fractions containing HA were pooled, concentrated and buffer-
exchanged into PBS (pH 8.0) (Gibco) using 100 kDa MWCO
(molecular-mass cut-off) spin columns (Millipore). The puriﬁed
proteinwasquantiﬁedusingtheBCA(bicinchoninicacid)method
(Pierce).
CD analysis of mutant HAs
CD analysis was performed using the Aviv Model 202 Circular
Dichroism Spectrometer. The spectra were generated between
190 and 280 nm (Supplementary Figure S1 at http://www.
BiochemJ.org/bj/444/bj4440429add.htm). Identical concentra-
tions of the mutant and wild-type proteins were used to avoid
any differences in the spectra arising from differences in their
concentrations.
Dose-dependent direct binding of wild-type and mutant HA
To investigate the multivalent HA–glycan interactions, a
streptavidin plate array comprising representative biotinylated
α2→3a n dα2→6 sialylated glycans was used as described
previously [15]. 3
 SLN (where S indicates the sialyl group
and LN is a type 2 lactosamine repeat unit), 3
 SLN-LN and
3
 SLN-LN-LN are representative avian receptors. 6
 SLN and
6
 SLN-LN are representative human receptors. The biotinylated
glycans were obtained from the Consortium for Functional
Glycomics through their resource request program. Streptavidin-
coated High Binding Capacity 384-well plates (Pierce) were
loaded to the full capacity of each well by incubating the well
with 50 μlo f2 . 4 μM biotinylated glycans overnight at 4◦C.
Excess glycans were removed through extensive washing with
PBS. The trimeric HA unit comprises three HA monomers
(and hence three RBSs, one for each monomer). The spatial
arrangement of the biotinylated glycans in the wells of
the streptavidin plate array favours binding to only one of the
three HA monomers in the trimeric HA unit. Therefore, in
order to speciﬁcally enhance the multivalency in the HA–glycan
interactions, the recombinant HA proteins were pre-complexed
withtheprimaryandsecondaryantibodiesatamolarproportionof
4:2:1 (HA/primary antibody/secondary antibody). The identical
arrangement of four trimeric HA units in the pre-complex for
all of the HAs permits comparison between their glycan-binding
afﬁnities. A stock solution containing appropriate amounts of
histidine-tagged HA protein, primary antibody (mouse anti-His6–
IgG from Abcam) and secondary antibody [HRP (horseradish
peroxidase)-conjugated goat anti-(mouse IgG) from Santa Cruz
Biotechnology] at a proportion of 4:2:1 were incubated on ice for
20 min. Appropriate amounts of pre-complexed stock HA were
diluted to 250 μl with 1% (w/v) BSA in PBS. Then, 50 μlo f
this pre-complexed HA was added to each of the glycan-coated
wells and incubated at room temperature (25◦C) for 3 h followed
by the wash steps with PBS and PBST (PBS containing 0.05%
Tween 20). The binding signal was determined based on HRP
activity using the Amplex Red Peroxidase Assay kit (Invitrogen)
according to the manufacturer’s instructions.
Calculation of SIN (Signiﬁcant Interaction Network) scores of RBS
residues in SC18, NY18 and AV18 HA
The SIN of an amino acid in a protein is a metric developed
previously by our group [16] to capture the extent of networking
of that amino acid in terms of its inter-residue contacts with
other amino acids in that protein. Starting from the co-ordinate
PDB ﬁle of a protein instances of putative hydrogen bonds
(including water-bridged ones), disulﬁde bonds, π-bonds, polar
interactions, salt bridges and Van der Waals interactions (non-
hydrogen) occurring between pairs of residues using appropriate
distance thresholds were computed using protocols implemented
inMATLAB(requiringBioinformaticsToolbox).Thesedatawere
assembled into an array of eight atomic interaction matrices.
A weighted sum of the eight atomic interaction matrices were
then computed to produce a single matrix that accounts for
the strength of atomic interaction between residue pairs, using
weights derived from relative atomic interaction energies and
including weights for interchain interactions and long-range over
short-range interactions. The resulting inter-residue energetic
interaction matrix describes all ﬁrst-order interactions for the
molecular structure analysed. All interaction pathways regardless
of length were then calculated to obtain the paths. Using the
collection of paths identiﬁed (and their corresponding scores),
the complete SIN matrix was created, wherein each element i, j is
the sum of the path scores of all paths. The degree of networking
score for each residue was computed by summing across the rows
of the matrix, which was meant to correspond to the extent of
‘networking’ for each residue. The degree of networking score
was normalized (SIN score) with the maximum score for each
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proteinsothatthescoresvariedfrom0(absenceofanynetwork)to
1(mostnetworked).Thehomologymodelsofthetrimericformof
SC18, NY18 and AV18 HA were constructed using the Modeller
program (http://salilab.org/modeller/) by adapting the python
scriptfromonlinedocumentationtomodelmultiplechainsrelated
by symmetry (http://salilab.org/modeller/manual/node28.html).
The template structure used for the modelling is that of SC18
HA (PDB code 1RUZ). These models were used to compute SIN
scores of each amino acid in the respective protein.
Digestion of H1N1 by Glu-C
In 50 mM ammonium bicarbonate solution, 10 μgo fH 1 N 1
was denatured with 6 M urea, and reduced by 25 mM DTT
(dithiothreitol) at 60◦C for 45 min. The mixture was then
cooled to room temperature. Iodoacetamide was added to a ﬁnal
concentration of 55 mM, and the mixture was incubated in the
dark at room temperature for 30 min to alkylate the cystine
residue. The mixture was then diluted with 50 mM ammonium
bicarbonate solution to reduce the urea concentration to 1 M.
Then, 0.5 μg of Glu-C (Sequencing Grade from Promega) was
added, and the mixture was incubated at room temperature
overnight to digest the H1N1 HA. The digestion reaction was
quenched by adding formic acid until the pH fell below 4.
MALDI-MS and MALDI–TOF/TOF (tandem time-of-ﬂight) MS
analysis of glycosylation sites on H1N1
The protein digest was desalted by ZipTip 0.6 μlC 18 resin
(Millipore)beforeMALDIanalysis.MSandMS/MSspectrawere
acquired on an Applied Biosystems 4800 Plus MALDI TOF/TOF
Analyzer, equipped with a 355 nm Nd:YAG (neodymium-doped
yttrium aluminium garnet) laser. A 5 mg/ml solution of α-cyano-
4-hydroxycinnamicacidin1:1(v/v)acetonitrile/waterwasusedas
the matrix. On a standard 384-well stainless steel MALDI sample
plate,0.5 μlofthedesaltedproteindigestand0.5 μlofthematrix
solutionwasspottedinonewell.Fiveduplicatesoftheabovespot
were made. One spot was used for MS analysis, and the rest were
used for MS/MS analysis. MS and MS/MS spectra were both
acquired under positive-ion reﬂector mode. For fragmentation,
2 kV acceleration voltage and CID (collision-induced
dissociation) mode off was applied. External peptide standards
were used for calibration.
RESULTS
Rationale for choice of HAs used in the present study
SC18 represents a prototypical human-adapted pandemic H1N1
virus. NY18 is a natural variant of SC18 that differs from its
parental virus by a single amino acid mutation (D225G) in the
RBS of HA. AV18 is a laboratory-generated recombinant virus
from SC18 that differs from SC18 by two amino acid mutations
(D190E/D225G). The glycan receptor speciﬁcity and afﬁnity of
the HA from these viruses have been well characterized [15,17].
SC18 HA shows strict speciﬁcity and high afﬁnity for human
receptors. On the other hand, AV18 HA shows strict speciﬁcity
and high afﬁnity for avian receptors. NY18 is an intermediate
between SC18 and AV18 since it shows a mixed human/avian
receptor binding, albeit at substantially lower afﬁnities than SC18
(forthehumanreceptor)andAV18(fortheavianreceptor).Given
that these viruses differ only in the RBS of HA, they have served
as good model strains to link glycan receptor speciﬁcity and
afﬁnity with other biological properties such as viral transmission
[17]. Whereas SC18 with speciﬁc high-afﬁnity binding to human
receptors transmitted readily via respiratory droplets in a ferret
animal model, AV18 did not show any such transmission. NY18,
on the other hand, was able to transmit via respiratory droplets,
albeit to a much lesser extent than SC18. Given the diversity of
glycan-binding preferences of SC18, NY18 and AV18 HAs and
differences in transmissibility of the viruses, these HAs served
as ideal model systems to study the effect of HA glycosylation
on HA–glycan interactions. These HAs were expressed in their
soluble form (lacking transmembrane region) with a His6 tag as
described previously [18].
Structural framework for identifying conserved glycosylation sites
in H1N1 HA that potentially affects glycan receptor binding
Building on a previous systematic analysis of sequons in H1N1
HAs from 1918 to the present [14] (Supplementary Table S1),
the sequon positions in the side and top of the head region of HA
were mapped on to a representative H1N1 crystal structure (PDB
code 1RUZ). Analysis of these sequon positions on the crystal
structure revealed that glycosylation at two speciﬁc residues,
Asn
91 and Asn
131, were positioned to interact with the 220-
loop and 130-loop regions of the RBS respectively (Figure 1A).
Among these two speciﬁc sequons, Asn
91 was observed in most
of the H1N1 HAs (except those isolated between 1933 and 1940),
including the recent strains after the 2009 pandemic, whereas
Asn
131 was observed only in H1N1 HAs in 1934–1985 isolates.
Therefore the effect of glycosylation at Asn
91 on glycan receptor
binding of SC18, NY18 and AV18 HAs was investigated further.
The co-ordinates of the core GlcNAc (N-acetylglucosamine)
sugar of the N-linked glycosylation at Asn
91 have been resolved
in the crystal structure of SC18 HA (PDB code 1RUZ). This
sugar interacts with Arg
224, which is a part of the 220-loop in the
RBS (Figure 1B). Lys
222 and Asp
225 in SC18 HA make critical
contacts with the Gal (galactose) sugar of the Neu5Acα2→6Gal-
motif in the human receptor [15,19]. On the other hand, in
AV18 HA, Glu
190 and Gln
226 make critical contacts with the
Neu5Acα2→3Gal- motif in the avian receptor. The relatively
lower-afﬁnity binding of NY18 to the human and avian receptors
hasbeenattributedtotheabsenceofthecriticalAsp
225 residue(for
human receptor contacts) and Glu
190 (for avian receptor contacts)
[15].
On the basis of these structural features of RBS and the
glycosylation site at Asn
91, it was hypothesized that any
perturbation in the 220-loop due to loss of glycosylation at Asn
91
is likely to affect human receptor binding of SC18 HA, but have a
relatively lesser effect on avian receptor binding of AV18 (given
additional stabilization by Glu
190 that is not a part of the 220-
loop). The 220-loop of NY18 HA makes fewer contacts with the
human receptor and NY18 HA also lacks the longer side chain
of Glu
190 for optimal contacts with the avian receptor. It was
therefore hypothesized that perturbation of the 220-loop due to
loss of glycosylation at Asn
91 would affect the binding of NY18
HAtobothavianandhumanreceptors.Toexperimentallytestthis
hypothesis, a single T93A amino acid change that abrogates the
sequonatAsn
91 (andhenceremovesglycosylationatthissite)was
introduced into SC18, NY18 and AV18 HAs. The glycan receptor
binding of the mutant HAs were analysed using dose-dependent
direct glycan binding on a glycan array platform.
Dose-dependent direct binding analysis of the T93A mutants on the
glycan array
The T93A mutant form of SC18 HA showed a characteristic
binding to the human receptor (6
 SLN-LN) (Figure 2) similar
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Figure 1 Structural framework for glycosylation at Asn91 affecting glycan receptor binding
(A) Composite H1N1 HA monomer structure (derived from PDB code 1RUZ) with the key regions in the RBS and sequons shown in Supplementary Table S1 (at http://www.BiochemJ.org/
bj/444/bj4440429add.htm) mapped on to the structure. (B) Structural complex of SC18 and NY18 with human receptor and AV18 with avian receptor where key residues involved in glycan receptor
binding are shown. Homology models of these structures were obtained on the basis of the SC18 crystal structure (PDB code 1RUZ). The ﬁrst GlcNAc sugar (indicated as GlcNAc-1) attached to
Asn91 critically interacts with Arg224 in all of the structures.
to the wild-type SC18 HA. However, the binding afﬁnity of
the mutant was substantially lower than that of the wild-type
protein. In the case of AV18, the T93A mutation did not alter
the speciﬁcity or binding afﬁnity to avian receptors (3
 SLN,
3
 SLN-LN and 3
 SLN-LN-LN) (Figure 2) in comparison with
the wild-type HA. Interestingly, the T93A mutation in NY18
completely abolished binding to both human and avian receptors
when compared with wild-type HA. Therefore these observations
validated our hypothesis on the basis of the structural framework.
Network-based description of RBS: additional insights into
observed differential effects of glycosylation
The SIN score calculated as described in the Materials and
methods section captures the extent of networking of inter-amino
acid interactions for each amino acid in the three-dimensional
structure of HA. The SIN score has been correlated previously
with constraints imposed on a residue in HA (including RBS) to
undergo mutations [16]. A high SIN score for a residue implied
that it is the most constrained from undergoing mutations since it
is highly networked in terms of interactions with surrounding
residues. A low SIN score, on the other hand, implied that
the residue is less constrained from undergoing mutations since it
is poorly networked. Comparison of the SIN scores of key RBS
residues showed that AV18 HA has the most networked residues
in RBS, followed by SC18 HA and then by NY18 HA (Figure 3).
Furthermore, the degree of networking of residues in RBS of
these HAs appears to correlate with their ability to retain glycan
receptor binding in the context of the loss of glycosylation at
Asn
91. Therefore, in addition to mutational constraints, the SIN
scores of the residues appear to be linked to properties governed
by the glycosylation of HA.
Characterization of glycosylation at Asn91
The effect of glycosylation at Asn
91 on receptor binding was
primarily attributed to interactions between Arg
224 and the ﬁrst
core GlcNAc sugar of glycan N-linked to Asn
91. The structure of
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Figure 2 Dose-dependent direct glycan binding of wild-type and loss of glycosylation mutant HAs
The dose-dependent direct binding of wild-type SC18, NY18 and AV18 HAs are adapted from our previous study [15]. Note that the human receptor (6 SLN-LN) binding drops from saturation at
20μg/ml for SC18 T93A mutant HA when compared with 2μg/ml for wild-type indicating substantial lowering of binding afﬁnity as result of loss of glycosylation. On the other hand, the drop
in binding from saturation for avian receptor (for example 3 SLN-LN) is the same between AV18 HA and its T93A mutant indicating that loss of glycosylation does not affect its avian receptor
binding. CD analysis was performed on the wild-type and mutant HAs to show that loss of glycosylation does not affect the overall stability and fold of the protein (Supplementary Figure S1 at
http://www.BiochemJ.org/bj/444/bj4440429add.htm).
Figure 3 SIN in RBS of SC18, NY18 and AV18 HAs
Surface rendering of the SC18, NY18 and AV18 RBS is shown in grey. The critical amino acids
that interact with glycan receptor and have a threshold level of inter-residue networking (SIN
score >0.1) are shown and coloured as follows. For each critical amino acid among the three
HAs,theonewithhighestSINscoreisshowninred,theonewithsecondhighestvalueisshown
in bright pink and one with lowest value is shown in dark pink.
the entire glycan at this site was characterized using MALDI-MS
and TOF/TOF fragmentation.
The location of Asn
91 in the SC18 HA sequence was such that
treatment with trypsin or Lys-C would result in a large peptide
that, together with the glycan mass, would have a high molecular
mass.Suchamolecularmassfragmentislikelytocausedetection
issues due to poor ionization in MALDI-MS. To circumvent
this issue, SC18 HA was digested using Glu-C (an enzyme
that cleaves after the C-terminus of glutamic acid) as many
glutamic acid residues ﬂank the Asn
91 sequon-containing peptide
(Figure 4A).
The glycopeptide peaks were identiﬁed on the basis of the
following criteria. First, they did not match any predicted
peptide mass peak upon simulating Glu-C digestion of
SC18 HA. Secondly, the mass of these peaks differed by
speciﬁc sugar units (such as hexose or N-acetylhexosamine).
Thirdly, MS/MS fragmentation proﬁles of these peaks look
similar given that the peptide fragment ions arise from the
same parent peptide ion that is differentially glycosylated.
An extensive search of the glycan structure database was
performed to identify glycan compositions whose combined
mass with the theoretical mass of peptide fragments containing
Asn
91 sequon matched the experimentally observed MALDI-
MS peaks. This analysis revealed that the compositions
corresponding to the trimannosyl core, Man-5, Man-6, Man-
7 and Man-8 glycans accurately matched the observed
experimental mass peaks (Figure 4B). These results indicate
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Figure 4 Characterization of glycan structure at Asn91
(A) Sequence of SC18 with sequons indicated in bold. The Asn91 sequon is underlined. The sites for cleavage of Glu-C protease are shown in grey. The glycopeptide fragment shown in a broken
box containing the Asn91 sequon when combined with glycan compositions having high-mannose structures matched experimental mass peaks. (B) Annotated experimental mass peaks of the
glycopeptide fragment shown in the broken box in (A). Only that part of the MALDI-MS proﬁle that matched this fragment is shown for clarity. The sequence of the glycopeptide fragment was
conﬁrmed further using MS/MS peptide fragmentation analysis. Circles are mannose sugar units and squares are GlcNAc sugar units.
that the Asn
91 site predominantly consists of high-mannose
type N-linked glycans. The MALDI-MS peptide/glycopeptide
proﬁling was also performed to conﬁrm that the T93A
mutation results in loss of glycosylation at the Asn
91 sequon
(Supplementary Figure S2 at http://www.BiochemJ.org/bj/
444/bj4440429add.htm).
DISCUSSION
Several studies have pointed to the overall relationship between
glycosylation states of HA in terms of number and structure
of N-linked glycans and its glycan receptor-binding property.
Glycosylation sites on HA are introduced or removed during
evolution of viruses as a way to change its epitope surface in
order to evade the host immune response. In the context of
these changing sequons between various viral strains over time,
even within a given subtype such as H1N1, there appear to
be highly conserved sequons across these different strains. In
addition to facilitating immune response evasion by the virus, the
glycans at these conserved sequons may contribute to other key
functionssuchasmaintainingstabilityofdifferentdomains(RBS,
membrane fusion, etc.).
The present study focused on understanding the functions of
one such conserved glycosylation sequon (Asn
91)i nH 1 N 1H A
using the SC18, NY18 and AV18 strains. These strains have
distinct biological properties in terms of their glycan receptor-
binding speciﬁcities that have been correlated with their ability
to transmit via respiratory droplets in the ferret animal model.
Analysis of HA crystal structures showed that glycosylation
at Asn
91 makes key contacts with residues that are a part of
the 220-loop of the RBS. As predicted from this analysis, loss
of glycosylation at Asn
91 affected human receptor binding of
SC18 and NY18 HA, but not avian receptor binding of AV18
HA. Notably, the loss of glycosylation at Asn
91 had the most
pronounced effect on NY18 HA by abrogating its binding to both
avian and human receptors. NY18 was a natural variant of SC18
isolatedfromafatalcaseduringthe1918pandemic.Thereforeour
resultshighlighttheimportantroleofthisconservedglycosylation
site in human receptor binding of H1N1 for efﬁcient replication
and sustainability in the human host.
In an earlier study, a new framework, termed SIN, was
developed to capture and quantify the network of inter-residue
interactions in HA. Using this framework, it was demonstrated
that mutations in antigenic residues that were spatially distant
from RBS residues on the three-dimensional HA structure, but
connected via the inter-residue network, impinge on the glycan
receptor-binding property of HA [16]. In the present study, we
computed SIN scores of the RBS residues in SC18, NY18
and AV18 HA. It was interesting to note that the extent of
networking of residues in the RBS captured by the SIN score
correlated with glycan receptor-binding properties in the context
of glycosylation at Asn
91. This correlation may pave the way
for future studies to understand the relationship between the
extent of networking of a residue and other factors governing
its stability, such as thermal motion, which is also inﬂuenced by
glycosylation.
The present study also demonstrated that the predominantly
observed glycosylation in this sequon is high-mannose-type
glycans. Previous studies have shown that one of the mutations
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involved in desensitizing H1N1 virus to the innate immune
response in mice leading to increased virulence and rapid
progression of disease is the loss of glycosylation at the Asn
91
sequon [13]. It has also been demonstrated that resistance
to cyanovirin-N, a high-mannose-binding lectin, is acquired
naturally by loss of glycosylation at Asn
91 during adaptation
of a seasonal H1N1 virus in mice [20]. Given that a key part
of the mouse innate immune response is binding of immune
lectins to high-mannose-type glycans on pathogens facilitating
their clearance [21], the presence of high-mannose-type glycans
at Asn
91 is consistent with these observations.
In summary, by integrating structure-based network-based
biochemical binding and glycan characterization analyses, the
present study provides the structural basis for the effect of
glycosylation at a conserved sequon in HA on the biological
functions of the virus, such as glycan receptor-binding speciﬁcity
and host adaptation.
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Figure S1 CD of wild-type and mutant HAs
CD analysis of wild-type and Asn91 loss-of-glycosylation mutant HAs. This analysis showsthat
the loss of glycosylation does not affect the overall protein fold and stability.
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Figure S2 MS analysis of loss of glycosylation resulting from the T93A mutation on HA
(A) MALDI–MS peak of recombinantly expressed and puriﬁed SC18 HA (monomer). (B) MALDI–MS peak of the recombinantly expressed and puriﬁed T93A mutant form (monomer) of SC18 HA.
The difference of ∼1366in m/z values of the predominant peaks between SC18 wild-type and T93A mutant HA is consistent with a loss of N-linked glycans with a composition of Hex6HexNAc2
(after accountingfor thereducingend hydroxygroup).(C)MALDI–MS analysisofpeptidesformedbydigestionofSC18T93AmutantHAwith Glu-C andMS/MS fragmentationofthepeptide(inset)
containing Asn91 (shown in red). Inspection of peptide mass and signature fragmentation ions conﬁrms the absence of glycosylation at Asn91 due to the T93A mutation that abrogates the sequon.
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Table S1 Glycosylation sequons in H1N1 HA
TheTableisadaptedfrom[1].ThesequonsarenumberedbasedontheSC18HAcrystalstructure
(PDB code 1RUZ).
Period Side of the head region of HA Top of the head region of HA
1918 91
1933 60 129 165
1934–1939 131
1940–1948 91 131 165
1949–1957 91 131 163
1977–1985 91 131 163
1986–2008 58 91 129 163
2009–present 91
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